Nervous System News and Research

Latest Nervous System News and Research

Omeros third quarter net loss increases to $7.6 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third quarter of 2010.

4 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Exposure to several AEDs in the womb negatively affect child's neurodevelopment

A large population-based study revealed that multiple antiepileptic drugs (AEDs) used by pregnant women to control seizures may cause poor school performance in their teenagers. The research team from Karolinska University Hospital and the University of Lund in Sweden confirmed that exposure to AEDs in utero may have a negative effect on neurodevelopment.

4 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

New noninvasive technique provides low-level electrical stimulation to reduce pain

A simple, noninvasive technique providing low-level electrical stimulation of the brain produces significant pain-reducing effects in humans, reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Vanda third quarter total revenue increases to $7.2 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2010.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009.

3 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Allen Institute releases new data and tools for exploring genes at work in human brain

The Allen Institute for Brain Science announced today its twentieth public data release, which includes new data and tools for exploring genes at work in the human brain. In addition to expanding and enhancing the Allen Human Brain Atlas, the Allen Institute launched two new human brain resources: the Ivy Glioblastoma Atlas Project and the NIMH Transcriptional Atlas of Human Brain Development.

3 Nov 2010

People hospitalized after stroke on a weekend more likely to die: Study

People admitted to the hospital on a weekend after a stroke are more likely to die compared to people admitted on a weekday, regardless of the severity of the stroke they experience, according to new research published in the November 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

3 Nov 2010

New mathematical modeling shows cellular basis of neural transmission

NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for nanodomains and transmitter release," in Nature Neuroscience on Oct. 17, 2010.

3 Nov 2010

Study suggests heredity may play a role in determining infant's susceptibility to AOP

A potentially life-threatening challenge characterized by pauses in breathing that can last for more than 20 seconds, apnea of prematurity (AOP) affects more than 50 percent of premature infants and is almost universal in the smallest of preemies. Caused in part by an underdeveloped central nervous system that can't adequately regulate breathing outside of the womb, especially during sleep, AOP is not yet fully understood by scientists and remains a grave concern among neonatologists and parents alike.

3 Nov 2010

Somaxon awarded $245,000 grant for Silenor under QTDP program

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

3 Nov 2010

Nervous System News and Research

Latest Nervous System News and Research

Omeros third quarter net loss increases to $7.6 million

Athersys secures three Therapeutic Discovery Project grants

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Phase III study suggests CYCLOSET tablets improve glycemic control

Exposure to several AEDs in the womb negatively affect child's neurodevelopment

Aestus receives $244,000 grant from QTDP program

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

New noninvasive technique provides low-level electrical stimulation to reduce pain

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Vanda third quarter total revenue increases to $7.2 million

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

Allen Institute releases new data and tools for exploring genes at work in human brain

People hospitalized after stroke on a weekend more likely to die: Study

New mathematical modeling shows cellular basis of neural transmission

Study suggests heredity may play a role in determining infant's susceptibility to AOP

Somaxon awarded $245,000 grant for Silenor under QTDP program

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in